Title 21Subpart

subpart 8—fees relating to biosimilar biological products

Contents

  1. § 379j–51. Definitions
  2. § 379j–52. Authority to assess and use biosimilar biological product fees
  3. § 379j–53. Reauthorization; reporting requirements